Psychedelic psychiatry’s brave new world. Nutt, D., Erritzoe, D., & Carhart-Harris, R. Cell, 2020, 181, (1), 24-28. Doi : 10.1016/j.cell.2020.03.020 After a legally mandated, decades-long global arrest of research on psychedelic drugs, investiga- tion of psychedelics in the context of psychiatric disorders is yielding exciting results. Outcomes of neuroscience and clinical research into 5-Hydroxytryptamine 2A (5-HT2A) receptor agonists, such as psilocybin, show promise for addressing a range of serious disorders, including depression and addiction. Introduction—Why the Psychedelic Revolution in Psychiatry? Research leading to the discovery of new pharmacological treatments for psychiat- ric disorders has been painfully slow. With a few exceptions, including the use of orexin [...]
Lire la suiteNouvelle classification du cannabis : le service minimum de la Commission des stupéfiants de l’ONU par L630 | Déc 2, 2020 | Communiqué https://l630.org/nouvelle-classification-du-cannabis-le-service-minimum-de-la-commission-des-stupefiants-de-lonu/ Ce 12 décembre, la Commission des stupéfiants des Nations-Unies a décidé de modifier la classification du cannabis au sein des conventions internationales. Le cannabis n’est plus classé comme un stupéfiant du tableau IV, c’est-à-dire ayant un potentiel d’abus fort et des effets nocifs importants, sans valeur thérapeutique notable. L630 réagit. COMMUNIQUE DE PRESSE. L630 se félicite de la décision de la Commission des Stupéfiants des Nations-Unies de retirer le cannabis du tableau des stupéfiants sans intérêt médical. Cette décision [...]
Lire la suiteMedicinal use of cannabis based products and cannabinoids Tom P. Freeman, Chandni Hindocha, Sebastian F. Green, Michael A. P. Bloomfield British Medical Journal, 2019, 365, l1141 doi : 10.1136/bmj.l1141 What you need to know • Cannabis based products for medicinal use contain cannabinoids derived from the cannabis plant, including Δ9-tetrahydrocannabinol (THC), cannabidiol (CBD), or a combination of THC and CBD. Synthetic cannabinoids for medicinal use typically mimic the effects of specific cannabinoids such as THC • THC is the constituent of cannabis that causes the “high,” whereas CBD is not intoxicating at typical doses. THC and CBD have contrasting mechanisms of action and therapeutic indications; THC [...]
Lire la suiteWhat to Know About Peyote Use By Buddy T Medically reviewed by Steven Gans, MD VeryWell Mind.com, Updated on February 14, 2020 https://www.verywellmind.com/how-long-does-peyote-stay-in-your-system-80310 kedsirin jaidee / Getty Images Peyote (Lophophora williamsii or Lophophora diffusa) is a small, spineless cactus that is found in the southwest United States, northern Mexico and Peru. The plant has been used for about six thousand years by native tribes for religious and healing purposes. Peyote's principal active ingredient is mescaline, a psychedelic compound that can also be man-made through chemical synthesis.1 The peyote buttons, protrusions found on the tops of the cactus plants, are usually dried and then chewed or [...]
Lire la suitePsychedelics and Psychedelic-Assisted Psychotherapy Collin M. Reiff, M.D., Elon E. Richman, M.D., Charles B. Nemeroff, M.D., Ph.D., Linda L. Carpenter, M.D., Alik S. Widge, M.D., Ph.D., Carolyn I. Rodriguez, M.D., Ph.D., Ned H. Kalin, M.D., William M. McDonald, M.D., and the Work Group on Biomarkers and Novel Treatments, a Division of the American Psychiatric Association Council of Research AJP in Advance, 2019, 1-20. doi: 10.1176/appi.ajp.2019.19010035 Objective : The authors provide an evidenced-based summary of the literature on the clinical application of psychedelic drugs in psychiatric disorders. Methods : Searches of PubMed and PsycINFO via Ovid were conducted for articles in English, in peer-reviewed journals, reportingon“psilocybin,” [...]
Lire la suiteConstructing drug effects : A history of set and setting Ido Hartogsohn Drug Science, Policy and Law, 2017, 3, (0) 1–17 Doi : 10.1177/2050324516683325 Abstract Set and setting is a term which refers to the psychological, social, and cultural parameters which shape the response to psychedelic drugs. The concept is considered fundamental to psychedelic research and has also been used to describe nonpharmacological factors which shape the effects of other agents such as alcohol, heroin, amphetamines, or cocaine. This paper reviews the history and evolution of the concept of set and setting from the 19th-century Parisian Club des Hashischins, through to 1950s psychotomimetic research on [...]
Lire la suiteAccounting for Microdosing Classic Psychedelics Blake Beaton, Heith Copes, Megan Webb, Andy Hochstetler, and Peter S. Hendricks Journal of Drug Issues, 2019, 1–12 Doi : 10.1177/0022042619871008 Abstract Microdosing classic psychedelics (e.g., LSD [lysergic acid diethylamide] and psilocybin) is the practice of taking small amounts of these substances to bring about various positive life changes. Little is known about the subjective experiences and perceptions of those who engage in the practice. Accordingly, we use the sociology of accounts as a theoretical framework to explore the ways that those who microdose excuse or justify their practice. Using data from semistructured interviews with 30 people who had microdosed, [...]
Lire la suite“Go Ask Alice”: The Case for Researching Schedule I Drugs Kenneth V. ISERSON Cambridge Quarterly of Healthcare Ethics, 2019, 28, 168–177. © Cambridge University Press 2018. doi : 10.1017/S0963180118000518 Abstract : The available treatments for disorders affecting large segments of the population are often costly, complex, and only marginally effective, and many have numerous side effects. These disorders include dementias, debilitating neurological disorders, the multiple types of drug addiction, and the spectrum of mental health disorders. Preliminary studies have shown that a variety of psychedelic and similar U.S. Drug Enforcement Administration Schedule I drugs may offer better treatment options than those that currently exist and pose potentially [...]
Lire la suite